ARGOS THERAPEUTICS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-6.22% | +78.50% |
| 2019 | Argos Therapeutics, Inc. Went Out of Business | CI |
| 2019 | First Amended Liquidation Plan Approved for Argos Therapeutics, Inc. | CI |
Presenter SpeechRichard Katz (Executives)Good morning, everybody, and thank you for joining us...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| +78.50% | 567K | |
| -3.51% | 86.13B | |
| +1.97% | 39.82B | |
| +56.59% | 25.23B | |
| -14.82% | 15.36B | |
| -8.82% | 11.95B | |
| -16.29% | 11.6B | |
| -41.58% | 11.51B | |
| +6.14% | 8.71B | |
| -9.71% | 8.12B |
- Stock Market
- Equities
- ARGSQ Stock
- News Argos Therapeutics, Inc.
- Transcript : Argos Therapeutics, Inc. - Special Call
